GSK pays $10.6B for Nuvalent, a 40% premium pivot back to oncology
The U.K. pharma giant lands its biggest deal in eight years to rebuild a trimmed cancer pipeline.
By Turki Al-Mutairi·· 3 min
13 briefings · “arm”
The U.K. pharma giant lands its biggest deal in eight years to rebuild a trimmed cancer pipeline.